Skip to main navigation Skip to search Skip to main content

The STAMP inhibitor asciminib is a novel therapy for ABL1-rearranged ALL.

Activity: Invited talks and oral presentations › Invited Keynote and Plenary Presentations

Description


Period12 May 2025 → 16 May 2025
Event titleInternational Society of Paediatric Oncology- Europe (SIOPE)
Event typeConference
Conference number6
LocationBudapest, HungaryShow on map
Degree of RecognitionInternational

Keywords

  • STAMP
  • Inhibitior
  • Asciminib
  • ABL1
  • ALL